The commercial, regulatory, and clinical management of hereditary angioedema (HAE) has undergone a rapid structural transformation following three major FDA approvals in 2025. For pharmacy and therapeutics (P&T) committees, medical directors, rare-disease specialty hub managers, and health plan market-access teams, evaluating HAE treatment access now requires navigating five distinct biological mechanism classes split between routine long-term prophylaxis and acute on-demand attack management.
Long-term prophylaxis in 2026 spans monoclonal activated Factor XIIa inhibition (Andembry / garadacimab-gxii, CSL Behring, 351(a) BLA 761367, approved June 16, 2025), plasma kallikrein inhibition via monoclonal antibody (Takhzyro / lanadelumab-flyo, BLA 761090) and oral small molecule (Orladeyo / berotralstat, NDA 214094), ligand-conjugated antisense prekallikrein knockdown (Dawnzera / donidalorsen-sodium, Ionis, NDA 219407, approved August 21, 2025), and subcutaneous C1-esterase inhibitor replacement (Haegarda).
Acute on-demand attack treatment has been similarly expanded with the approval of the first oral plasma-kallikrein inhibitor (Ekterly / sebetralstat, KalVista, NDA 219301, approved July 3, 2025), alongside established C1-INH replacements (Berinert, Ruconest), the plasma-kallikrein inhibitor Kalbitor (ecallantide, BLA 125277, provider-administered medical benefit), and the bradykinin B2-receptor antagonist Firazyr (icatibant acetate, NDA 022150), which is now heavily genericized with 10 ANDA approvals in the FDA Orange Book.
+---------------------------------------------------------------------------------------------------------+
| HEREDITARY ANGIOEDEMA THERAPY MATRIX |
+---------------------------------------------------------------------------------------------------------+
| ROUTINE LONG-TERM PROPHYLAXIS |
| - Factor XIIa Monoclonal Ab: Andembry (garadacimab-gxii, SC Monthly) |
| - Plasma Kallikrein Monoclonal Ab: Takhzyro (lanadelumab-flyo, SC q2w/q4w) |
| - Oral Plasma Kallikrein Small Molecule: Orladeyo (berotralstat, Daily Capsule) |
| - Antisense Prekallikrein Knockdown: Dawnzera (donidalorsen, SC Monthly/q2m) |
| - Subcutaneous C1-INH Replacement: Haegarda (C1-esterase inhibitor human, SC 2x/week) |
+---------------------------------------------------------------------------------------------------------+
| ACUTE ON-DEMAND ATTACK MANAGEMENT |
| - Oral Plasma Kallikrein Small Molecule: Ekterly (sebetralstat, Oral Tablet at Attack Onset) |
| - Bradykinin B2 Receptor Antagonist: Icatibant (Firazyr & 10 Generic ANDAs, SC Self-Administered) |
| - Intravenous C1-INH Replacement: Berinert (Human) / Ruconest (Recombinant) |
| - Recombinant Kallikrein Inhibitor: Kalbitor (ecallantide, SC Provider-Administered Medical Benefit) |
+---------------------------------------------------------------------------------------------------------+
Payers route all self-administered subcutaneous and oral agents (Andembry, Dawnzera, Orladeyo, Takhzyro, Haegarda, Ekterly, and icatibant) through the pharmacy benefit, reserving medical benefit administration for provider-infused Kalbitor or clinic-administered acute therapies. Because HAE annual treatment costs range from $450,000 to over $635,000 per patient for baseline prophylaxis—and can exceed $1,000,000 annually for poorly controlled patients experiencing frequent breakthrough swelling attacks requiring acute intervention—payer prior authorization (PA) criteria strictly enforce laboratory-confirmed C1-inhibitor deficiency or dysfunction.
Building upon specialty benefit frameworks established in the hemophilia access landscape roctavian withdrawal altuviiio hemlibra alhemo hemgenix, the sickle cell disease treatment access landscape, and site of care edits iv subcutaneous specialty drugs, this analysis provides a definitive regulatory, clinical, and access guide to HAE therapy in 2026.
What HAE treatments are FDA-approved in 2026, and how do the five mechanism classes differ?
Hereditary angioedema is a rare, life-threatening autosomal dominant disorder caused by mutations in the SERPING1 gene (leading to C1-esterase inhibitor deficiency in Type I HAE or dysfunction in Type II HAE) or mutations in F12, PLG, ANGPT1, KNG1, or MYOF (HAE with normal C1-INH). Uncontrolled activation of the contact system leads to excess bradykinin generation, causing recurrent, unpredictable localized edema in peripheral skin, gastrointestinal abdominal walls, and upper respiratory airways.
+---------------------------------------------------------------------------------------------------------+
| THE CONTACT-KININ PATHWAY AND HAE TARGETING POINTS |
+---------------------------------------------------------------------------------------------------------+
Factor XII ---> [ Inhibited by ANDEMBRY (garadacimab) ] ---> Factor XIIa
|
v
Prekallikrein ---> [ Inhibited by DAWNZERA (donidalorsen RNAi) ] ---> Plasma Kallikrein
|
|---> [ Inhibited by TAKHZYRO,
| ORLADEYO, EKTERLY, KALBITOR ]
v
High-MW Kininogen -------------------------------------------------> Bradykinin
|
v
[ Blocked by ICATIBANT ] ----------------------------------------> Bradykinin B2 Receptor
|
v
Vascular Permeability & Swelling
The 2026 FDA-approved HAE therapy roster spans five distinct biological mechanism classes:
+---------------------------------------------------------------------------------------------------------------------------+
| COMPLETE 2026 HAE FDA-APPROVED THERAPY ROSTER |
+------------------------+------------------+-------------------------+---------------+------------+------------------------+
| Product (Brand/Generic)| Sponsor | Mechanism Class | FDA Pathway | Route/Freq | Indication & Scope |
+------------------------+------------------+-------------------------+---------------+------------+------------------------+
| Andembry (garadacimab) | CSL Behring | Factor XIIa Monoclonal | BLA 351(a) | SC Monthly | Prophylaxis (Age 12+) |
| Takhzyro (lanadelumab) | Takeda / Dyax | Plasma Kallikrein mAb | BLA 761090 | SC q2w/q4w | Prophylaxis (Age 2+) |
| Orladeyo (berotralstat)| BioCryst | Oral Kallikrein Small M | NDA 214094 | Oral Daily | Prophylaxis (Age 12+) |
| Dawnzera (donidalorsen)| Ionis Pharma | Antisense Prekallikrein | NDA 219407 | SC Monthly | Prophylaxis (Age 12+) |
| Haegarda (C1-INH SubQ) | CSL Behring | C1-INH Replacement (Hum)| BLA 125606 | SC 2x/wk | Prophylaxis (Age 6+) |
| Cinryze (C1-INH IV) | Takeda / ViroPh. | C1-INH Replacement (Hum)| BLA 125267 | IV 2x/wk | Prophylaxis (Age 6+) |
| Ekterly (sebetralstat) | KalVista Pharma | Oral Kallikrein Small M | NDA 219301 | Oral Acute | Acute Attack (Age 12+) |
| Firazyr (icatibant) | Takeda / Generics| Bradykinin B2 Antagonist| NDA 022150* | SC Acute | Acute Attack (Age 18+) |
| Berinert (C1-INH IV) | CSL Behring | C1-INH Replacement (Hum)| BLA 125287 | IV Acute | Acute Attack (All Ages)|
| Ruconest (C1-INH Rec.) | Pharming Group | C1-INH Replacement (Rec)| BLA 125495 | IV Acute | Acute Attack (Age 13+) |
| Kalbitor (ecallantide) | Takeda / Dyax | Recombinant Kallikrein | BLA 125277 | SC Acute | Acute Attack (Age 12+)|
+------------------------+------------------+-------------------------+---------------+------------+------------------------+
*Note: Firazyr NDA 022150 is referenced by 10 generic ANDAs approved in the Orange Book.
Detailed Mechanism Class Breakdown
- Factor XIIa Inhibitors: Activated Factor XII (FXIIa) is the initiating serine protease of the contact cascade. By inhibiting FXIIa, Andembry (garadacimab-gxii) prevents both autoactivation of FXII and conversion of plasma prekallikrein to kallikrein, acting at the top of the inflammatory cascade.
- Plasma Kallikrein Inhibitors: Plasma kallikrein cleaves high-molecular-weight kininogen (HMWK) to liberate free bradykinin. Inhibitors of plasma kallikrein span three distinct drug formats: subcutaneous monoclonal antibodies (Takhzyro), daily oral small molecules (Orladeyo), and on-demand oral tablets (Ekterly).
- Antisense Prekallikrein Knockdown: Rather than binding circulating protein, Dawnzera (donidalorsen-sodium) degrades target mRNA in hepatocytes, reducing plasma prekallikrein protein production by over 80% to eliminate the enzyme precursor altogether.
- C1-Esterase Inhibitor Replacement: Direct physiological replacement of missing or dysfunctional endogenous C1-INH protein using plasma-derived human C1-INH (Haegarda, Cinryze, Berinert) or recombinant human C1-INH produced in transgenic rabbit milk (Ruconest).
- Bradykinin B2 Receptor Antagonists: Firazyr (icatibant) acts at the end of the cascade, competitively blocking the binding of free bradykinin to vascular endothelial B2 receptors to arrest ongoing fluid extravasation and mucosal edema.
How do the three 2025 approvals (Andembry, Ekterly, Dawnzera) change prophylaxis and acute care?
The 2025 approval trio addressed three major unmet clinical and operational needs in HAE management: upstream pathway inhibition, oral acute therapy, and subcutaneous RNA-targeted prophylaxis.
1. Andembry (garadacimab-gxii): Factor XIIa Monoclonal Antibody
Approved on June 16, 2025, Andembry (garadacimab-gxii, CSL Behring, 351(a) BLA 761367) represents the first fully human IgG4 monoclonal antibody targeting activated Factor XII (FXIIa). By binding the catalytic domain of FXIIa, Andembry stops the contact cascade at its initiating step, preventing FXIIa from cleaving plasma prekallikrein into active kallikrein.
In the pivotal Phase 3 VANGUARD trial (published in The Lancet), monthly subcutaneous administration of garadacimab achieved a 89.2% reduction in mean monthly HAE attack rates compared to placebo ($p < 0.0001$). Furthermore, 62% of patients receiving garadacimab remained completely attack-free during the 26-week treatment period. Supplied as a single-dose 200 mg/mL prefilled autoinjector, Andembry provides a monthly self-administered prophylactic option that avoids the biweekly dosing burden of early lanadelumab regimens.
2. Ekterly (sebetralstat): The First Oral Acute Attack Therapy
Approved on July 3, 2025 (announced July 7, 2025), Ekterly (sebetralstat, KalVista Pharmaceuticals, NDA 219301) solved a multi-decade patient challenge: the requirement for parenteral injection during acute angioedema attacks. Ekterly is an oral, selective small-molecule inhibitor of plasma kallikrein.
In the pivotal Phase 3 KONFIDENT trial, patients taking a single oral dose of sebetralstat (600 mg, two 300 mg tablets) at the earliest onset of an HAE attack experienced rapid symptom relief, with median time to beginning of symptom relief of 1.61 hours compared to 6.72 hours for placebo ($p < 0.0001$).
[ Attack Onset ] ---> Oral EKTERLY (sebetralstat 600mg) ---> Symptom Relief in 1.6 Hours
(No Needle, No Reconstitution, No Refrigeration)
The ability to treat attacks immediately with an oral tablet—without needing to thaw blood-derived C1-INH or administer subcutaneous injections of generic icatibant—dramatically reduces time to treatment, preventing severe attack progression and emergency department visits.
3. Dawnzera (donidalorsen-sodium): Subcutaneous Antisense RNAi Prophylaxis
Approved on August 21, 2025, Dawnzera (donidalorsen-sodium, Ionis Pharmaceuticals, NDA 219407) brought RNA therapeutics directly into HAE management. Dawnzera is a ligand-conjugated antisense (LICA) oligonucleotide that targets plasma prekallikrein (KLKB1) mRNA in hepatocytes.
In the pivotal Phase 3 OASIS-HAE trial (published in The New England Journal of Medicine), donidalorsen administered subcutaneously once every 4 weeks or once every 8 weeks achieved a 81% to 87% reduction in mean monthly attack rates versus placebo. In the 3-week to 25-week assessment window, monthly dosing reduced attack rates by 90%, with 41% of patients achieving total attack freedom over the entire trial. Delivered via an autoinjector, Dawnzera establishes an RNA-knockdown prophylactic regimen competing directly against Takhzyro and Andembry.
Which HAE agents are biologics (Purple Book) versus NDA drugs (Orange Book), and why does icatibant now have generics?
Understanding the legal regulatory classification of HAE agents is vital for legal counsel, generics manufacturers, and specialty pharmacies. HAE therapies fall into two distinct regulatory categories: 351(a) Biologics License Applications (BLAs) listed in the FDA Purple Book, and Section 505(b) New Drug Applications (NDAs) listed in the FDA Orange Book.
+---------------------------------------------------------------------------------------------------------+
| PURPLE BOOK VS. ORANGE BOOK HAE ROSTER |
+------------------------------------+------------------------------------+-------------------------------+
| FDA Registry | Product / Active Ingredient | Regulatory Pathway & BLA/NDA |
+------------------------------------+------------------------------------+-------------------------------+
| PURPLE BOOK | Andembry (garadacimab-gxii) | BLA 761367 |
| (Biologics & Monoclonals) | Takhzyro (lanadelumab-flyo) | BLA 761090 |
| | Cinryze (C1-INH Human) | BLA 125267 |
| | Haegarda (C1-INH Human SubQ) | BLA 125606 |
| | Berinert (C1-INH Human IV) | BLA 125287 |
| | Ruconest (C1-INH Recombinant) | BLA 125495 |
| | Kalbitor (ecallantide) | BLA 125277 |
+------------------------------------+------------------------------------+-------------------------------+
| ORANGE BOOK | Orladeyo (berotralstat) | NDA 214094 / NDA 219776 |
| (Small Molecules & Oligos) | Ekterly (sebetralstat) | NDA 219301 |
| | Dawnzera (donidalorsen-sodium) | NDA 219407 |
| | Firazyr (icatibant acetate) | NDA 022150 (Brand) |
| | Generic Icatibant (10 ANDAs) | Abbreviated NDAs (ANDAs) |
+------------------------------------+------------------------------------+-------------------------------+
The Icatibant Genericization Wave
Firazyr (icatibant acetate, Shire/Takeda, NDA 022150) was approved by the FDA in 2011 as a synthetic 10-amino-acid peptidomimetic B2-receptor antagonist. Because icatibant is a chemically synthesized peptide rather than a cell-culture biologic, it was approved via an NDA under Section 505(b) of the FD&C Act.
Following patent expirations, the FDA Orange Book records 10 approved Abbreviated New Drug Applications (ANDAs) for generic icatibant injection (30 mg/3 mL prefilled syringes), held by Fresenius Kabi (ANDA 208317), Teva (ANDA 210118), Jiangsu Hansoh (ANDA 211021), Wilshire (ANDA 211501), Nang Kuang (ANDA 212081), Cipla (ANDA 212446), Caplin (ANDA 213054), Glenmark (ANDA 213222), Eugia (ANDA 213521), and Alembic (ANDA 213773).
The availability of 10 generic ANDAs has turned icatibant into the lowest-cost first-line acute attack option for health plans, driving down unit acquisition costs and causing payers to mandate generic icatibant step-therapy before approving brand-name acute options or provider-administered acute biologics.
Chemically Synthesized Oligonucleotides as NDAs
Crucially, Dawnzera (donidalorsen-sodium) is listed in the Orange Book under NDA 219407, not the Purple Book. Under FDA regulatory definitions, chemically synthesized oligonucleotides and ASOs are regulated as small-molecule drug products under Section 505 of the FD&C Act rather than biologics under Section 351 of the PHS Act. This structural distinction governs generic entry, patent listing rules, and Hatch-Waxman exclusivity.
How do payers route HAE drugs across pharmacy versus medical benefit, and what prior-authorization criteria apply?
Because hereditary angioedema therapies are among the most expensive chronic specialty regimens in biopharma, commercial health plans, PBMs (Express Scripts, CVS Caremark, OptumRx), and regional Blues plans (such as Prime Therapeutics / Regence) enforce strict benefit routing and prior authorization (PA) algorithms.
+---------------------------------------------------------------------------------------------------------+
| PAYER BENEFIT ROUTING AND TIERING MAP |
+---------------------------------------------------------------------------------------------------------+
| PHARMACY BENEFIT (Self-Administered Specialty Pharmacy Channel) |
| - Routine Prophylaxis: Andembry, Takhzyro, Dawnzera, Orladeyo, Haegarda |
| - Acute On-Demand: Ekterly (Oral), Generic Icatibant (SubQ Prefilled Syringe) |
| - PA Requirements: Confirmed C1-INH lab value + documented attack frequency threshold (>=2/month) |
+---------------------------------------------------------------------------------------------------------+
| MEDICAL BENEFIT (Buy-and-Bill / Provider-Administered Infusion Channel) |
| - Acute On-Demand: Kalbitor (ecallantide - provider SubQ due to anaphylaxis black box warning) |
| - IV Prophylaxis / Acute: Cinryze, Berinert, Ruconest (clinic IV infusion) |
| - Site-of-Care Edits: Mandate shift from hospital outpatient infusion to home self-administration |
+---------------------------------------------------------------------------------------------------------+
Payer Prior-Authorization (PA) Standard Criteria
To receive plan coverage for HAE prophylaxis or acute therapy, commercial PA guidelines typically require:
- Laboratory Confirmation of Diagnosis:
- Type I HAE: Documented low C1-INH antigenic level ($<50%$ of lower limit of normal) AND low C4 level.
- Type II HAE: Documented normal/elevated C1-INH antigenic level BUT low C1-INH functional level ($<50%$ of normal) AND low C4 level.
- HAE with Normal C1-INH: Confirmed pathogenic mutation in F12, PLG, ANGPT1, or KNG1, OR documented recurrent angioedema with family history and failure of high-dose antihistamines.
- Prophylaxis Baseline Attack Threshold:
- Requirement of at least 2 severe, documented swelling attacks per month (or history of laryngeal attacks) despite avoidance of triggers.
- Preferred Prophylaxis Formulary Tiering:
- Payers frequently place self-administered subcutaneous biologics/ASOs (Andembry, Takhzyro, Dawnzera, Haegarda) or oral Orladeyo on Preferred Specialty Tiers, requiring documented failure or contraindication before approving non-preferred IV replacement therapies.
- Acute Attack Formulary Mandatory Step-Therapy:
- Mandatory first-line use of generic icatibant or oral Ekterly under the pharmacy benefit before authorizing higher-cost branded acute agents or provider-administered Kalbitor.
Comparative Prophylaxis Agent Economics and Efficacy
When designing formularies, pharmacy benefit managers (PBMs) require comparative matrices mapping annual wholesale acquisition cost (WAC) against pivotal trial efficacy and administration burden.
+---------------------------------------------------------------------------------------------------------------------------------+
| 2026 HAE PROPHYLAXIS: EFFICACY, DOSING, AND ECONOMIC COMPARISON |
+----------------------+--------------------+---------------------+-----------------------------+---------------------------------+
| Agent (Brand) | Route & Frequency | WAC/List Price/Yr | Pivotal Trial Efficacy | Payer Utilization Dynamics |
+----------------------+--------------------+---------------------+-----------------------------+---------------------------------+
| Takhzyro | SubQ q2w or q4w | ~$635,000 | ~87% attack reduction | Historical market leader; PA |
| (lanadelumab) | Self-administered | (Historical ref) | (HELP trial) | often requires failure of oral. |
+----------------------+--------------------+---------------------+-----------------------------+---------------------------------+
| Andembry | SubQ Monthly | TBD/Estimated | 89.2% attack reduction | Highest-tier efficacy; targets |
| (garadacimab-gxii) | Self-administered | | (VANGUARD trial) | patients with frequent attacks. |
+----------------------+--------------------+---------------------+-----------------------------+---------------------------------+
| Orladeyo | Oral Daily Capsule | ~$480,000 | ~44% attack reduction | Preferred for convenience; |
| (berotralstat) | Self-administered | (Historical ref) | (APeX-2 trial) | lower absolute efficacy tier. |
+----------------------+--------------------+---------------------+-----------------------------+---------------------------------+
| Dawnzera | SubQ Monthly/q2m | TBD/Estimated | 81-90% attack reduction | RNAi profile competes directly |
| (donidalorsen) | Self-administered | | (OASIS-HAE trial) | with mAbs (Andembry/Takhzyro). |
+----------------------+--------------------+---------------------+-----------------------------+---------------------------------+
| Haegarda | SubQ Twice Weekly | ~$500,000 | ~95% attack reduction | Physiologic replacement; high |
| (C1-INH Human) | Self-administered | (Historical ref) | (COMPACT trial) | burden of bi-weekly dosing. |
+----------------------+--------------------+---------------------+-----------------------------+---------------------------------+
(Note: Pricing references reflect historically available public WAC data. Newer agents may launch with undisclosed or value-based net pricing structures.)
What is the Kalbitor (ecallantide) medical-benefit exception, and why does it require provider administration?
While self-administered subcutaneous and oral agents dominate the modern pharmacy benefit landscape, Kalbitor (ecallantide) remains uniquely positioned under the medical benefit due to strict safety requirements. Kalbitor is a recombinant plasma kallikrein inhibitor approved for acute attacks in patients 12 and older.
However, unlike generic icatibant or oral Ekterly, Kalbitor carries an FDA Black Box Warning for anaphylaxis. Because clinical trials revealed a risk of severe hypersensitivity reactions—which can be clinically indistinguishable from a severe HAE laryngeal attack—the FDA mandated that Kalbitor must only be administered by a healthcare provider in a setting equipped to manage anaphylaxis.
This requirement completely eliminates Kalbitor from the self-administered specialty pharmacy channel. Payers route Kalbitor exclusively through the medical benefit (buy-and-bill). From a clinical positioning standpoint, as patients increasingly prefer immediate at-home symptom relief via oral Ekterly or self-injected icatibant, Kalbitor is largely reserved for patients who present to clinics or emergency departments with severe attacks, or those who have failed other acute interventions.
How does HAE type affect treatment selection and prior-authorization criteria?
The underlying genetic and pathophysiologic etiology of a patient's HAE fundamentally dictates both their treatment eligibility and the evidence required by payers to approve six-figure therapies.
HAE is broadly categorized into three distinct pathophysiological types:
- Type I HAE (C1-INH Deficiency): Accounts for roughly 85% of cases. Caused by mutations in the SERPING1 gene, resulting in low quantitative production of the C1-esterase inhibitor protein.
- Type II HAE (C1-INH Dysfunction): Accounts for approximately 15% of cases. Also caused by SERPING1 mutations, but results in the production of normal or elevated amounts of a functionally defective C1-INH protein.
- HAE with Normal C1-INH (HAEnC1): A rarer, highly heterogeneous subset. These patients have normal quantitative and functional C1-INH levels but harbor mutations in genes such as F12 (Factor XII), PLG (Plasminogen), ANGPT1 (Angiopoietin-1), or KNG1 (Kininogen-1).
Diagnostic Mapping to PA Requirements
For Types I and II, commercial prior-authorization (PA) criteria explicitly require laboratory confirmation of low C1-INH antigenic levels or functional activity ($<50%$ of normal) combined with depressed C4 levels. Because the diagnostic biomarkers are universally agreed upon, PA approval is relatively straightforward once laboratory evidence is submitted.
Conversely, obtaining PA approval for HAE with normal C1-INH is notoriously difficult. Because routine C1-INH and C4 lab values return normal, medical directors often demand targeted genetic sequencing demonstrating pathogenic F12, PLG, or ANGPT1 mutations. In the absence of a confirmed genetic mutation, payers typically require extensive documentation of recurrent, life-threatening swelling attacks (particularly laryngeal edema, which carries a high fatality risk from asphyxiation) and a documented failure to respond to high-dose antihistamines and corticosteroids, definitively ruling out histaminergic angioedema. Without this rigorous documentation, payers frequently deny access to $500,000+ prophylactic agents, misclassifying the patient's condition as idiopathic chronic spontaneous urticaria.
How does Dawnzera (donidalorsen antisense) connect HAE to the broader RNA-therapeutics modality?
The approval of Dawnzera (donidalorsen) establishes a direct bridge between rare disease clinical access and the broader advanced RNA therapeutics platform detailed in RNA therapeutics clinical trials by the numbers 2026.
[ Donidalorsen LICA ASO ] ---> Subcutaneous Autoinjector Injection
|
v
[ GalNAc Targeted to ASGPR Receptor ]
|
v
[ Receptor-Mediated Endocytosis into Hepatocyte ]
|
v
[ RNase H1 Cleavage of KLKB1 Prekallikrein mRNA ]
|
v
[ Sustained 80%+ Reduction in Plasma Kallikrein ]
Donidalorsen utilizes Ionis's Ligand-Conjugated Antisense (LICA) chemistry. By attaching a triantennary GalNAc cluster to a 2'-O-methoxyethyl (2'-MOE) modified phosphorothioate gapmer ASO, donidalorsen achieves precise receptor-targeted delivery to hepatocytes while avoiding systemic toxicities.
Inside the hepatocyte nucleus, donidalorsen binds complementary target sequences on KLKB1 pre-mRNA, recruiting endogenous RNase H1 to cleave the transcript. This reduces liver production of plasma prekallikrein by over 80%, eliminating the primary substrate required for bradykinin generation.
Dawnzera's clinical success proves that GalNAc-conjugated antisense oligonucleotides can compete directly with potent monoclonal antibodies (Takhzyro, Andembry) in systemic rare diseases, offering comparable efficacy with extended dosing intervals (every 4 or 8 weeks) and smaller injection volumes.
What is the realistic 2026 to 2029 commercial and regulatory outlook for HAE management?
Over the next three years, the HAE therapeutic market will experience significant commercial and regulatory developments, driven by intense competition among the five established mechanism classes:
- Pediatric Indication Expansions and Clinical Trials: The race to capture the pediatric market is accelerating. Both KalVista (evaluating sebetralstat/Ekterly in young children) and Ionis (advancing pediatric cohorts for donidalorsen/Dawnzera) are executing aggressive pediatric trial expansions targeting children aged 2 to 11. Historically, pediatric HAE management relied heavily on cumbersome IV infusions of plasma-derived C1-INH. By expanding oral acute tablets and low-volume, monthly subcutaneous RNA prophylaxis into early childhood, these newer agents aim to fully displace legacy IV replacements in pediatric specialty care, drastically reducing the treatment burden on caregivers and pediatric hospitals.
- Oral vs. Injectable Prophylaxis Share Shift: P&T committees are meticulously monitoring the real-world market share balance between daily oral prophylaxis (Orladeyo) and highly potent, extended-interval autoinjectors (Andembry, Dawnzera, Takhzyro). While the daily oral convenience of Orladeyo appeals to many patients, its lower attack-reduction efficacy (~40-50% reduction in pivotal data) compared to the >80-90% reduction seen with Andembry and Dawnzera leads prescribers to stratify patients. Oral prophylaxis is frequently reserved for mild-to-moderate attack phenotypes, while the highly potent RNAi and mAb therapies are deployed for severe patients with life-threatening airway involvement.
- Value-Based Contracting and Cost Containment: With baseline HAE prophylaxis costs averaging $450,000 to $635,000 per patient annually, PBMs are leveraging the unprecedented competition among five mechanism classes to extract maximum rebate concessions. Outcome-based value contracts—where sponsors are required to reimburse the health plan if a patient experiences more than a specified number of breakthrough attacks per year—are rapidly becoming the standard across specialty pharmacy contracting for Andembry, Dawnzera, and Takhzyro.
- Cross-Therapeutic Analogies in Rare Disease: The rapid pivot from intravenous enzyme replacement to subcutaneous RNA-targeted therapies and oral small molecules seen in HAE closely mirrors structural shifts in other rare diseases. Specialty directors evaluating the HAE budget impact are applying similar benefit design frameworks to emerging cardiovascular markets, as detailed in the cardiac amyloidosis ATTR-CM access landscape.
How do the five HAE prophylaxis agents compare on efficacy, dosing, and estimated annual cost?
For P&T committees, formulary analysts, and specialty pharmacy directors constructing HAE formulary tiers, the following comparison synthesizes available clinical and pricing data across all five approved long-term prophylaxis options. Annual cost estimates reflect wholesale acquisition cost (WAC) ranges available from public disclosures and industry analyses; actual net costs after rebates vary substantially by payer contract.
+-------------------------------------------------------------------------------------------------------------------------+
| HAE LONG-TERM PROPHYLAXIS: HEAD-TO-HEAD COMPARISON |
+------------------------+-----------------------+------------------------+-----------------------+------------------------+
| Attribute | Andembry (garadacimab) | Takhzyro (lanadelumab) | Dawnzera (donidalorsen)| Orladeyo (berotralstat) |
+------------------------+-----------------------+------------------------+-----------------------+------------------------+
| Mechanism | Factor XIIa mAb | Plasma Kallikrein mAb | Antisense PKK ASO | Oral Kallikrein Inhib. |
| FDA Pathway | BLA 351(a) | BLA 761090 | NDA 219407 | NDA 214094 |
| Route | SC Autoinjector | SC Prefilled Syringe | SC Autoinjector | Oral Capsule |
| Dosing Frequency | Monthly (q4w) | q2w or q4w | Monthly or q8w | Daily |
| Self-Administered? | Yes | Yes | Yes | Yes |
| Pivotal Attack Red. | 89.2% vs Placebo | 87% (q2w) vs Placebo | 81-87% vs Placebo | 44% vs Placebo |
| Attack-Free Patients | 62% (26 wks) | 44% (q2w, 26 wks) | 41% (25 wks) | Not reported (low) |
| Refrigeration Req. | Yes (2-8°C) | Yes (2-8°C) | Yes (2-8°C) | No (Room Temperature) |
| Age Indication | ≥12 years | ≥2 years | ≥12 years | ≥12 years |
| Est. Annual WAC Range | ~$450K-$550K/yr (est.) | ~$575K-$635K/yr | ~$450K-$525K/yr (est.)| ~$480K-$500K/yr |
+------------------------+-----------------------+------------------------+-----------------------+------------------------+
| Haegarda (C1-INH) | |
+------------------------+---------------------------------------------------------------------------------------------+
| Mechanism: C1-INH Replacement (Plasma-Derived Human) |
| Route: SC (60 IU/kg 2x/week); FDA Pathway: BLA 125606; Self-Administered: Yes; Est. WAC: ~$450K-$550K/yr |
| Efficacy: 95% attack reduction vs placebo in COMPACT trial; requires twice-weekly injection and reconstitution |
+-------------------------------------------------------------------------------------------------------------------------+
Key Formulary Decision Points
Efficacy Stratification: The most striking differentiator is the efficacy gap between high-potency parenteral agents and oral prophylaxis. Andembry, Takhzyro, Dawnzera, and Haegarda all demonstrated >80% attack-rate reductions in pivotal trials, while Orladeyo achieved approximately 44% reduction. This efficacy stratification drives many P&T committees to reserve Orladeyo for mild-to-moderate attack phenotypes and patients who strongly prefer oral dosing despite the reduced protection.
Dosing Convenience: Monthly autoinjector dosing (Andembry, Dawnzera monthly regimen) represents the lowest injection burden. Takhzyro at the every-4-week maintenance dose offers comparable convenience. Dawnzera's option for every-8-week dosing in some patients provides an additional advantage for adherence-sensitive populations. Haegarda's requirement for twice-weekly subcutaneous reconstitution and injection represents the highest self-administration burden.
Pediatric Access: Takhzyro (approved for ages ≥2) and Haegarda (approved for ages ≥6) offer the broadest pediatric coverage. Andembry, Dawnzera, and Orladeyo are currently limited to ages ≥12, though pediatric extension trials are in progress.
What is the clinical risk of untreated laryngeal HAE attacks, and how does this affect formulary urgency?
Hereditary angioedema carries a unique fatality risk that distinguishes it from most chronic specialty conditions: laryngeal angioedema attacks can cause death by asphyxiation within hours if untreated. Before the modern therapeutic era, the estimated lifetime mortality rate from a single laryngeal attack in undiagnosed or untreated HAE patients was reported at approximately 25-30% in historical case series, and undiagnosed HAE was associated with unnecessary tracheotomies and fatalities.
This mortality risk has three important implications for formulary decision-making:
Emergency Acute Medication Access: Every HAE patient on prophylaxis must also carry a prescribed acute attack medication for breakthrough episodes. Formulary coverage must pair prophylaxis approval with concurrent authorization for at least one acute agent (Ekterly, generic icatibant, or C1-INH). Payer denials that leave patients without accessible acute therapy during the prior-authorization review period create genuine life-safety risk.
Step-Therapy Limitations: While payers routinely impose step-therapy requirements for chronic specialty drugs, imposing a mandatory step-through lower-efficacy agents (e.g., requiring 6 months of Orladeyo failure before authorizing Andembry or Dawnzera) carries clinical risk for patients with laryngeal-predominant attack patterns. Clinical guidelines from the US Hereditary Angioedema Association (HAEA) and World Allergy Organization (WAO) explicitly recommend against delaying access to high-efficacy prophylaxis in patients with a history of upper-airway involvement.
Emergency Department Preparedness: Despite advances in self-administered therapy, many emergency departments remain unfamiliar with HAE-specific management. Patients presenting with abdominal or facial swelling are frequently misdiagnosed with allergic angioedema and treated with epinephrine and corticosteroids, which are ineffective against bradykinin-mediated HAE. The availability of oral Ekterly for self-treatment before hospital arrival represents a potentially practice-changing intervention for reducing ED presentations and misdiagnosis-related delays.
Frequently Asked Questions
Is there an oral treatment for hereditary angioedema?
Yes. As of 2026, there are two FDA-approved oral treatments for HAE: Orladeyo (berotralstat, approved in 2020), a daily oral capsule taken for long-term routine prophylaxis; and Ekterly (sebetralstat, approved July 3, 2025), an oral tablet taken at the earliest onset of an acute angioedema attack.
What is the difference between Andembry, Takhzyro, and Orladeyo for HAE prophylaxis?
Andembry (garadacimab-gxii) is a monthly subcutaneous monoclonal antibody targeting activated Factor XIIa. Takhzyro (lanadelumab-flyo) is a subcutaneous monoclonal antibody targeting plasma kallikrein given every 2 or 4 weeks. Orladeyo (berotralstat) is a daily oral small-molecule inhibitor of plasma kallikrein.
Is Dawnzera (donidalorsen) a biologic or an antisense drug?
Dawnzera (donidalorsen-sodium) is a chemically synthesized ligand-conjugated antisense oligonucleotide (LICA ASO) targeting prekallikrein mRNA. Regulated by the FDA as a small-molecule drug under Section 505 of the FD&C Act (NDA 219407), it is listed in the FDA Orange Book rather than the Purple Book.
Is icatibant (Firazyr) available as a generic?
Yes. Generic icatibant acetate (30 mg/3 mL prefilled syringe for subcutaneous injection) is widely available with 10 FDA-approved ANDAs in the Orange Book, serving as a first-line, lower-cost acute attack therapy under health plan pharmacy benefits.
Sources
- KalVista Pharmaceuticals (2025). KalVista Pharmaceuticals Announces FDA Approval of EKTERLY (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema. Primary FDA approval release. KalVista News.
- U.S. Food and Drug Administration (FDA). Purple Book: Database of Licensed Biological Products. Official biologics database export (July 2026). Records for Andembry (BLA 761367), Takhzyro (BLA 761090), Cinryze (BLA 125267), Kalbitor (BLA 125277), Haegarda (BLA 125606), Berinert (BLA 125287), Ruconest (BLA 125495). FDA Purple Book.
- U.S. Food and Drug Administration (FDA). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Official drug database export (July 2026). Records for Orladeyo (NDA 214094), Dawnzera (NDA 219407), Ekterly (NDA 219301), Firazyr (NDA 022150 and 10 ANDAs). FDA Orange Book.
- Prime Therapeutics / Regence (2025). Medications for Hereditary Angioedema Program Summary. Pharmacy benefit routing and PA criteria. Regence MyPrime.
- CSL Behring (2025). Andembry (garadacimab-gxii) Market Access Dossier & VANGUARD Phase 3 Study. CSL Behring Immunology. CSL Market Access.
- Ionis Pharmaceuticals (2024). Donidalorsen in Hereditary Angioedema: Pivotal Phase 3 OASIS-HAE Results. New England Journal of Medicine, 391:21-31. NEJM OASIS-HAE.
- MedImpact HealthCare Systems. Payer Drug Intelligence Report: Hereditary Angioedema Specialty Cost Management. MedImpact Client News.
